NASDAQ:NLTX

Neoleukin Therapeutics Competitors

$11.97
-0.11 (-0.91 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.77
Now: $11.97
$12.18
50-Day Range
$11.26
MA: $12.12
$13.20
52-Week Range
$9.63
Now: $11.97
$18.13
Volume121,176 shs
Average Volume252,371 shs
Market Capitalization$506.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09

Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) Vs. RVNC, DRNA, AXSM, NGM, MORF, and KURA

Should you be buying NLTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Neoleukin Therapeutics, including Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), Morphic (MORF), and Kura Oncology (KURA).

Neoleukin Therapeutics (NASDAQ:NLTX) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Earnings and Valuation

This table compares Neoleukin Therapeutics and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66

Neoleukin Therapeutics has higher revenue and earnings than Revance Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neoleukin Therapeutics and Revance Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neoleukin Therapeutics00603.00
Revance Therapeutics00503.00

Neoleukin Therapeutics currently has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Revance Therapeutics has a consensus target price of $36.40, indicating a potential upside of 29.40%. Given Neoleukin Therapeutics' higher probable upside, equities analysts clearly believe Neoleukin Therapeutics is more favorable than Revance Therapeutics.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are owned by institutional investors. 7.1% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Neoleukin Therapeutics and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neoleukin TherapeuticsN/A-24.06%-21.92%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Summary

Neoleukin Therapeutics beats Revance Therapeutics on 9 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Neoleukin TherapeuticsN/A-24.06%-21.92%

Earnings & Valuation

This table compares Dicerna Pharmaceuticals and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96

Neoleukin Therapeutics has higher revenue and earnings than Dicerna Pharmaceuticals. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dicerna Pharmaceuticals and Neoleukin Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
Neoleukin Therapeutics00603.00

Dicerna Pharmaceuticals currently has a consensus target price of $37.8333, indicating a potential upside of 45.01%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Neoleukin Therapeutics' higher probable upside, analysts plainly believe Neoleukin Therapeutics is more favorable than Dicerna Pharmaceuticals.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Axsome Therapeutics (NASDAQ:AXSM) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Neoleukin TherapeuticsN/A-24.06%-21.92%

Valuation & Earnings

This table compares Axsome Therapeutics and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96

Axsome Therapeutics has higher earnings, but lower revenue than Neoleukin Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Axsome Therapeutics and Neoleukin Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Neoleukin Therapeutics00603.00

Axsome Therapeutics currently has a consensus target price of $146.90, indicating a potential upside of 177.22%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Axsome Therapeutics' higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Neoleukin Therapeutics.

Volatility & Risk

Axsome Therapeutics has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Summary

Neoleukin Therapeutics beats Axsome Therapeutics on 7 of the 12 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NGM Biopharmaceuticals and Neoleukin Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Neoleukin Therapeutics00603.00

NGM Biopharmaceuticals currently has a consensus target price of $39.1111, indicating a potential upside of 53.80%. Neoleukin Therapeutics has a consensus target price of $22.6667, indicating a potential upside of 89.36%. Given Neoleukin Therapeutics' higher probable upside, analysts clearly believe Neoleukin Therapeutics is more favorable than NGM Biopharmaceuticals.

Valuation & Earnings

This table compares NGM Biopharmaceuticals and Neoleukin Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96

NGM Biopharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NGM Biopharmaceuticals and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Neoleukin TherapeuticsN/A-24.06%-21.92%

Summary

Neoleukin Therapeutics beats NGM Biopharmaceuticals on 9 of the 15 factors compared between the two stocks.

Neoleukin Therapeutics (NASDAQ:NLTX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 61.5% of Morphic shares are held by institutional investors. 7.1% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 39.5% of Morphic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Neoleukin Therapeutics and Morphic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neoleukin Therapeutics00603.00
Morphic00203.00

Neoleukin Therapeutics presently has a consensus price target of $22.6667, indicating a potential upside of 89.36%. Morphic has a consensus price target of $63.3333, indicating a potential upside of 6.71%. Given Neoleukin Therapeutics' higher possible upside, equities research analysts clearly believe Neoleukin Therapeutics is more favorable than Morphic.

Earnings & Valuation

This table compares Neoleukin Therapeutics and Morphic's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06

Morphic has lower revenue, but higher earnings than Neoleukin Therapeutics. Morphic is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neoleukin Therapeutics and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neoleukin TherapeuticsN/A-24.06%-21.92%
MorphicN/A-36.62%-20.69%

Summary

Neoleukin Therapeutics beats Morphic on 8 of the 12 factors compared between the two stocks.

Neoleukin Therapeutics (NASDAQ:NLTX) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Risk & Volatility

Neoleukin Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500.

Institutional & Insider Ownership

65.7% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 94.7% of Kura Oncology shares are held by institutional investors. 7.1% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 11.0% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations for Neoleukin Therapeutics and Kura Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neoleukin Therapeutics00603.00
Kura Oncology011002.91

Neoleukin Therapeutics presently has a consensus price target of $22.6667, indicating a potential upside of 89.36%. Kura Oncology has a consensus price target of $39.5455, indicating a potential upside of 38.42%. Given Neoleukin Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neoleukin Therapeutics is more favorable than Kura Oncology.

Earnings & Valuation

This table compares Neoleukin Therapeutics and Kura Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.92

Kura Oncology has lower revenue, but higher earnings than Neoleukin Therapeutics. Kura Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neoleukin Therapeutics and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neoleukin TherapeuticsN/A-24.06%-21.92%
Kura OncologyN/A-30.96%-28.02%


Neoleukin Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71Analyst Report
News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
News Coverage
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.